Institutional investors purchased a net $1.3 million shares of ENTA during the quarter ended December 2017. This may signal that the smart money is gaining interest in this company as the 74.24% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FARALLON CAPITAL MANAGEMENT LLC Bought 512.7 Thousand shares of Enanta Pharmaceuticals In...
T. ROWE PRICE ASSOCIATES, INC. Bought 269.6 Thousand shares of Enanta Pharmaceuticals In...